Best of ASCO® Montreal 2024: Lung Cancer – Dr. Jonathan Spicer
OR
Co-Chairs
Dr. Jamil Asselah
Dr. Kim Ma
Speakers
Dr. Jonathan Spicer
Studies/trials discussed:
- KRYSTAL-12: Phase 3 study of adagrasib versus docetaxel in patients with previously treated advanced/metastatic non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation.
- Subcutaneous versus Intravenous Amivantamab, both in Combination with Lazertinib, in Refractory EGFR-mutated NSCLC: Primary Results from the Phase 3 PALOMA-3 Study
- Lorlatinib Versus Crizotinib in Patients With Advanced ALK-Positive Non–Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study
- BEAT-meso: A randomized phase III study of bevacizumab (B) and standard chemotherapy (C) with or without atezolizumab (A), as first-line treatment (TX) for advanced pleural mesothelioma (PM)—Results from the ETOP 13-18 trial.
- Randomized Phase II/III Trial of Maintenance Systemic Therapy Versus Local Consilidative Therapy (LCT) Plus Maintenance Systemic Therapy For Limited Metastic Non-Small Cell Lung Cancer
- Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non–Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study
- Consolidative Radiotherapy for Limited Metastatic Non-Small-Cell Lung Cancer: A Phase 2 Randomized Clinical Trial
- Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial
- ADRIATIC: Durvalumab (D) as consolidation treatment (tx) for patients (pts) with limited-stage small-cell lung cancer (LS-SCLC).
- Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC
- Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer
- Outcomes with Perioperative Durvalumab in Patients with Resectable NSCLC and Baseline N2 Lymph Node Involvment
- Clinical outcomes with perioperative nivolumab (NIVO) by nodal status among patients (pts) with stage III resectable NSCLC: Results from the phase 3 CheckMate 77T study.
